TABLE 2.
Positive isolation rates for different viruses according to sample typea
| Sample type | No. of patients with positive results/total no. of patients tested (%)
|
|||||||
|---|---|---|---|---|---|---|---|---|
| First half of study (n = 471)
|
Second half of study (n = 254)
|
|||||||
| HEV71 (n = 167) | CVA16 (n = 80) | Any HEV (n = 255) | All (n = 389) | HEV71 (n = 106) | CVA16 (n = 19) | Any HEV (n = 153) | All (n = 239) | |
| Rectal | 65/166 (39) | 22/78 (28) | 100/252 (40) | 100/378 (27) | 38/103 (37) | 7/16 (44) | 68/147 (46) | 68/229 (30) |
| Throat | 127/164 (77) | 50/76 (66) | 191/248 (77) | 191/367 (52) | 66/104 (64) | 9/15 (60) | 101/148 (68) | 101/231 (44) |
| Vesicle | 66/111 (60) | 36/57 (63) | 106/167 (63) | 106/222 (47) | 54/81 (67) | 10/13 (77) | 63/97 (65) | 63/127 (50) |
| Ulcer | 36/85 (42) | 11/42 (26) | 53/129 (41) | 53/188 (28) | 28/87 (32) | 7/15 (47) | 44/117 (38) | 44/185 (24) |
| Serum | 0/9 (0) | 1/3 (33) | 1/10 (10) | 1/20 (5) | 2/26 (8) | 1/11 (9) | 6/43 (14) | 6/61 (10) |
| CSF | 2/43 (5) | 0/11 (0) | 2/58 (3) | 2/96 (2) | 0/29 (0) | 0/0 (0) | 1/42 (2) | 1/60 (2) |
a
The number of patients with positive results for each sample type is shown as a proportion of the HEV71-positive patients, the CVA16-positive patients, all HEV-positive patients, and all patients (whether their samples tested positive or negative). Eleven patients in the first half of the study and three in the second half of the study had co-isolation of HEV71 and CVA16.